Literature DB >> 17521698

Extrapulmonary small cell carcinomas express K homology domain containing protein overexpressed in cancer, but carcinoid tumors do not.

Rochelle Simon1, Patricia A Bourne, Qi Yang, Betsy O Spaulding, Paul A di Sant'Agnese, Hanlin L Wang, Haodong Xu.   

Abstract

A number of malignancies, including high-grade neuroendocrine carcinomas of the lung, have been reported to express K homology domain containing protein overexpressed in cancer (KOC), a member of the insulin-like growth factor messenger RNA-binding protein (IMP) family also known as L523S and IMP3. KOC acts to promote tumor cell proliferation by enhancing insulin-like growth factor-II protein expression. This study aimed to examine KOC expression pattern in extrapulmonary neuroendocrine tumors. Seventy-five extrapulmonary neuroendocrine tumors that were surgically resected or had undergone biopsy, including 53 small cell carcinomas (uterine cervix, 21; bladder, 10; colorectum, 13; prostate, 7; stomach, 1; and esophagus, 1) and 22 carcinoid tumors (colorectum, 10; appendix, 5; ileum, 4; duodenum, 2; and stomach, 1), were immunohistochemically studied using a monoclonal antibody against KOC. Our results demonstrated that 47 small cell carcinomas (89%) showed moderate to strong positive staining for KOC, with 25 cases (53%) showing positivity in more than 90% of tumor cells and 22 cases (47%) in 40% to 80% of tumor cells. Three cases showed weak staining in 5% to 10% of the tumor cells. The remaining 3 cases (uterine cervix, 2; bladder, 1) showed completely negative immunoreactivity. No KOC immunostaining was detected in 22 carcinoid tumors. These findings indicate that KOC may play an important role in the regulation of biologic behavior of extrapulmonary small cell carcinomas. In addition, immunohistochemical detection of KOC expression may serve as a useful diagnostic tool in the distinction between small cell carcinoma and carcinoid tumor, particularly when the diagnostic material is a small biopsy with crushing artifact.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17521698     DOI: 10.1016/j.humpath.2007.02.001

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  12 in total

1.  Expression and clinical significance of IMP3 in microdissected premalignant and malignant pancreatic lesions.

Authors:  B-J Wang; L Wang; S-Y Yang; Z-J Liu
Journal:  Clin Transl Oncol       Date:  2014-09-03       Impact factor: 3.405

2.  Fatty Acid Synthase and Acetyl-CoA Carboxylase Are Expressed in Nodal Metastatic Melanoma But Not in Benign Intracapsular Nodal Nevi.

Authors:  Jad Saab; Maria Laureana Santos-Zabala; Massimo Loda; Edward C Stack; Travis J Hollmann
Journal:  Am J Dermatopathol       Date:  2018-04       Impact factor: 1.533

3.  Role of the RNA-binding protein IMP-2 in muscle cell motility.

Authors:  Selim Boudoukha; Sylvain Cuvellier; Anna Polesskaya
Journal:  Mol Cell Biol       Date:  2010-10-18       Impact factor: 4.272

4.  Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors.

Authors:  Magdalena Slosar; Poonam Vohra; Manju Prasad; Andrew Fischer; Robert Quinlan; Ashraf Khan
Journal:  Endocr Pathol       Date:  2009       Impact factor: 3.943

5.  Analysis of IMP3 expression in normal and neoplastic human pituitary tissues.

Authors:  Alberto Righi; Shuya Zhang; Long Jin; Bernd W Scheithauer; Kalman Kovacs; Gabor Kovacs; Miklos I Goth; Marta Korbonits; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2010-03       Impact factor: 3.943

6.  IMP-3 expression in keratoacanthomas and squamous cell carcinomas of the skin: an immunohistochemical study.

Authors:  S Soddu; E Di Felice; S Cabras; M E Castellanos; L Atzori; G Faa; L Pilloni
Journal:  Eur J Histochem       Date:  2013-02-14       Impact factor: 3.188

7.  Insulin-like growth factor II mRNA binding protein 3 (IMP3) is overexpressed in prostate cancer and correlates with higher Gleason scores.

Authors:  Kristian Ikenberg; Florian R Fritzsche; Ursina Zuerrer-Haerdi; Irina Hofmann; Thomas Hermanns; Helge Seifert; Michael Müntener; Maurizio Provenzano; Tullio Sulser; Silvia Behnke; Josefine Gerhardt; Ashkan Mortezavi; Peter Wild; Ferdinand Hofstädter; Maximilian Burger; Holger Moch; Glen Kristiansen
Journal:  BMC Cancer       Date:  2010-06-30       Impact factor: 4.430

8.  Regulation of IMP3 by EGFR signaling and repression by ERβ: implications for triple-negative breast cancer.

Authors:  S Samanta; V M Sharma; A Khan; A M Mercurio
Journal:  Oncogene       Date:  2012-01-23       Impact factor: 9.867

9.  Expression of insulin-like growth factor-II mRNA-binding protein-3 as a marker for predicting clinical outcome in patients with esophageal squamous cell carcinoma.

Authors:  Akihiro Takata; Shuji Takiguchi; Kaoru Okada; Tsuyoshi Takahashi; Yukinori Kurokawa; Makoto Yamasaki; Hiroshi Miyata; Kiyokazu Nakajima; Masaki Mori; Yuichiro Doki
Journal:  Oncol Lett       Date:  2014-08-20       Impact factor: 2.967

Review 10.  Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression?

Authors:  Jessica L Bell; Kristin Wächter; Britta Mühleck; Nikolaos Pazaitis; Marcel Köhn; Marcell Lederer; Stefan Hüttelmaier
Journal:  Cell Mol Life Sci       Date:  2012-10-16       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.